Reports Q1 revenue $143.5M, consensus $123.39M. The company said, “Overall, we are very pleased with our first quarter performance, which we believe underscores the unique attributes of our business and the ability to deliver strong top and bottom-line financial results. We are confident in our ability to sustain this momentum through 2025 and beyond by remaining laser focused on operational execution and leveraging the unrivaled capabilities of OCS NOP to expand the utilization of available donor organs for transplantation. Ultimately, this will enable us to deliver what we believe to be the best possible clinical outcomes and most cost-efficient therapy for our transplant patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group options imply 14.5% move in share price post-earnings
- TransMedics price target raised to $105 from $90 at Piper Sandler
- TransMedics Group’s OCS Drives Structural Transformation in Liver Transplantation with Increased DCD Liver Utilization
- TransMedics Group: Strong Buy Rating Amidst Robust DCD Market Performance and Growth Prospects
- TransMedics Group: Strong Market Position and Growth Potential Justify Buy Rating